44820 Federal Register / Vol. 82, No. 185 / Tuesday, September 26, 2017 / Notices 

The review panel will make selections 

based upon the following criteria: 

Phase 1 

Accessibility 

• Is the proposed intervention easily 

utilized by families of diverse economic, 

social, and cultural backgrounds? Is it 

functional across disciplines/users? 

Measurability 

• How easily will the proposed 

intervention be evaluated in order to 

determine its efficacy (in both lab 

testing and in the real world)? Is the 

proposed intervention measurable 

among various audiences? 

Sustainability 

• Does the proposed intervention 

compel users to utilize the technology 

often and/or for long periods of time? 

Does it fit into daily life? Is it fun to use? 

Impact 

• Does the applicant present a theory 

or explanation of how the proposed 

intervention would result in concrete 

change? 

Phase 2 

Impact 

• How did the intervention impact 

outcomes for providers and patients? 

What did data show? 

Evidence Base 

• Is the intervention grounded in 

existing science related to improving 

health care and related services for 

pregnant women? 

Sustainability 

• Was the intervention compelling to 

users and did it encourage users to use 

the technology often? Did users want to 

continuously engage with the 

technology? 

Implementation 

• How feasible is the intervention? 

How much support for implementation 

will the intervention require (estimated 

financial and time commitment)? 

Phase 3 

Impact 

• How effective was the intervention 

when implemented at scale? Did the 

impacts on users from Phase 2 remain 

consistent? 

Implementation 

• How feasible was the intervention 

on a larger scale? How much support for 

implementation did the model require 

(financial and time commitment)? How 

challenging was the actual program 

implementation? 

Scalability 

• How costly was the intervention in 

a real-world setting? How likely are cost 

efficiencies for program delivery at 

greater scale? Can the technology be 

used in existing platforms? 

Additional Information 

General Conditions: 

• HRSA reserves the right to cancel, 

suspend, and/or modify the contest, or 

any part of it, for any reason, at HRSA’s 

sole discretion. 

• The interventions submitted across 

all phases should not use the HHS or 

HRSA logos or official seals in the 

submission, and must not claim 

endorsement. 

Intellectual Property 

• Each entrant retains full ownership 

and title in and to their submission. 

Entrants expressly reserve all 

intellectual property rights not 

expressly granted under the challenge 

agreement. 

• By participating in the challenge, 

each entrant hereby irrevocably grants 

to HRSA a limited, non-exclusive, 

royalty-free, worldwide license and 

right to reproduce, publically perform, 

publically display, and use the 

submission for internal HHS business 

and to the extent necessary to 

administer the challenge, and to 

publically perform and publically 

display the submission, including, 

without limitation, for advertising and 

promotional purposes relating to the 

challenge. 

• Record Retention and FOIA: All 

materials submitted to HRSA as part of 

a submission become HRSA records and 

cannot be returned. Any confidential 

commercial information contained in a 

submission should be designated at the 

time of submission. Participants will be 

notified of any Freedom of Information 

Act requests for their submissions in 

accordance with 45 CFR 5.65. 

Dated: September 19, 2017. 

George Sigounas, 

Administrator. 

[FR Doc. 2017–20539 Filed 9–25–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Notice of Non-Competitive, 

Supplemental Funding Award for Ryan 

White HIV/AIDS Program, Special 

Projects of National Significance 

AGENCY: Health Resources and Services 

Administration (HRSA), HHS. 

ACTION: Notice. 

SUMMARY: This non-competitive award 

will provide Secretary’s Minority AIDS 

Initiative Fund (SMAIF) supplemental 

funding to the Jurisdictional Approach 

to Curing Hepatitis C among HIV/HCV 

Coinfected People of Color—Evaluation 

and Technical Assistance Center 

(ETAC), RAND Corporation. This 

supplemental funding will allow RAND 

Corporation to provide evaluation and 

technical assistance to cooperative 

agreement recipients and subrecipient 

clinical sites under HRSA–17–047 

Curing Hepatitis C among People of 

Color Living with HIV. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award: 

RAND Corporation (U90HA30519). 

Amount of Non-Competitive Award: 

Up to $250,000 per year for 3 years 

(pending availability of future year 

funding). 

Period of Funding: September 30, 

2017, through September 29, 2020. 

CFDA Number: No. 93.928. 

Authority: The Consolidated 

Appropriations Act, 2017 (Pub. L. 115– 

31), Division H, Title II. 

Justification: In fiscal year (FY) 2016, 

the SMAIF Curing Hepatitis C among 

People of Color Living with HIV 

initiative was launched through three 

funding opportunities: (1) Jurisdictional 

Approach to Curing Hepatitis C among 

HIV/HCV Co-infected People of Color— 

Jurisdictional Sites (HRSA–16–189) and 

(2) Jurisdictional Approach to Curing 

Hepatitis C among HIV/HCV Coinfected 

People of Color—State Health 

Departments Coordinating Center 

(HRSA–16–195) to provide HIV primary 

medical care to low income, uninsured, 

and underserved people living with 

both HIV and hepatitis C virus (HCV); 

and (3) Jurisdictional Approach to 

Curing Hepatitis C among HIV/HCV 

Coinfected People of Color—ETAC 

(HRSA–16–188) to provide evaluation 

and technical assistance to the funded 

sites. In FY17, HRSA–17–047 was 

announced to improve HCV prevention 

and care; improve coordination to 

linkage and retention in care; and 

enhance capacity of health department 

Federal Register / Vol. 82, No. 185 / Tuesday, September 26, 2017 / Notices 44821 

surveillance systems to monitor HIV/ 

HCV coinfections among low-income or 

underinsured, racial and ethnic 

minority populations. HRSA–17–047 

recipients and subrecipients will require 

similar evaluation and technical 

assistance in order to meet the 

program’s goals and objectives. 

Supplemental funding to the existing 

ETAC is a cost effective and efficient 

solution that will leverage RAND 

Corporation’s currently funded 

infrastructure to include the additional 

sites funded under HRSA–17–047. 

Further, this supplemental funding will 

leverage RAND’s current work by 

combining and comparing evaluation 

results across all jurisdictions from both 

initiatives and facilitate the streamlining 

and integration of processes and 

technical assistance. Supplemental 

funding will also provide opportunities 

for RAND Corporation to create joint 

learning networks and build on lessons 

learned from the initial cohort of 

jurisdictional sites currently in the 

second year of implementation. Not 

issuing this award would result in a lack 

of evaluation and technical assistance 

for HRSA–17–047 recipients and 

subrecipients, which is critical to 

achieving the initiative’s goal to cure 

HCV among HIV/HCV coinfected people 

of color. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Adan Cajina, Chief, Demonstration 

Evaluation Branch, Office of Training 

and Capacity Development, Division of 

HIV Domestic Programs, HIV/AIDS 

Bureau, HRSA, 5600 Fishers Lane, 

09N108, Rockville, MD 20857, Phone: 

(301) 443–3180, Email: acajina@

hrsa.gov. 

Dated: September 19, 2017. 

George Sigounas, 

Administrator. 

[FR Doc. 2017–20544 Filed 9–25–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Frederick National 

Laboratory Advisory Committee to the 

National Cancer Institute. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

will also be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting Web site (http://

videocast.nih.gov/). 

Name of Committee: Frederick National 

Laboratory Advisory Committee to the 

National Cancer Institute 

Date: October 30, 2017. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: Ongoing and new activities at the 

Frederick National Laboratory for Cancer 

Research. 

Place: National Institutes of Health, 31 

Center Drive, Building 31, Wing C; 6th Floor, 

Conference Room 10, Bethesda, MD 20892. 

Contact Person: Caron A. Lyman, Ph.D. 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 9609 

Medical Center Drive, Room 7W–126, 

Bethesda, MD 20892, 240–276–6348 

lymanc@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/fac/fac.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 20, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20487 Filed 9–25–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the NHLBI Special Emphasis 

Panel. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Grant Review for NHLBI K Award Recipients. 

Date: October 17, 2017. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Suite 7202, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Melissa E Nagelin, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7202, Bethesda, MD 20892, 301–435–0297, 

nagelinmh2@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 20, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20489 Filed 9–25–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the